ATE509032T1 - Chimerizierte gm-csf antikörper - Google Patents

Chimerizierte gm-csf antikörper

Info

Publication number
ATE509032T1
ATE509032T1 AT03713430T AT03713430T ATE509032T1 AT E509032 T1 ATE509032 T1 AT E509032T1 AT 03713430 T AT03713430 T AT 03713430T AT 03713430 T AT03713430 T AT 03713430T AT E509032 T1 ATE509032 T1 AT E509032T1
Authority
AT
Austria
Prior art keywords
antibodies
chimerized
disclosed
well
fusion proteins
Prior art date
Application number
AT03713430T
Other languages
English (en)
Inventor
Christoph Renner
Andrew Scott
Antony Burgess
Original Assignee
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Res Ltd filed Critical Ludwig Inst For Cancer Res Ltd
Application granted granted Critical
Publication of ATE509032T1 publication Critical patent/ATE509032T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03713430T 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper ATE509032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35583802P 2002-02-13 2002-02-13
PCT/US2003/004185 WO2003068920A2 (en) 2002-02-13 2003-02-12 Humanized gm-csf antibodies

Publications (1)

Publication Number Publication Date
ATE509032T1 true ATE509032T1 (de) 2011-05-15

Family

ID=27734567

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Country Status (8)

Country Link
US (5) US7381801B2 (de)
EP (2) EP1507859B1 (de)
JP (1) JP2006500905A (de)
AT (2) ATE444308T1 (de)
AU (2) AU2003217386B2 (de)
DE (1) DE60329489D1 (de)
ES (1) ES2365606T3 (de)
WO (2) WO2003068924A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US7381801B2 (en) * 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
CA2566950A1 (en) 2004-07-02 2006-01-12 Wilex Ag Improved adjuvant therapy of g250-expressing tumors
EP2468774A3 (de) * 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antikörperneutralisierer des menschlichen Granulozyten-Makrophagenkolonie-stimulierenden Faktors
EP3620171B1 (de) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf-antikörper und verwendungen dafür
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091420A1 (es) * 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
CN101932603A (zh) * 2008-01-15 2010-12-29 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗骨质流失病症的方法
US8075885B2 (en) * 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
NZ588850A (en) * 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
CN102171247A (zh) * 2008-07-02 2011-08-31 特鲁比昂药品公司 TNF-α拮抗剂多靶点结合蛋白
EP2320942B1 (de) * 2008-07-21 2018-03-14 Probiodrug AG Diagnostischer antikörper-assay
ES2533493T3 (es) * 2008-08-20 2015-04-10 Probiodrug Ag Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato
EP3056217B1 (de) 2008-12-22 2021-06-30 The University of Melbourne Behandlung von osteoarthritis
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
CN103221422B (zh) 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
EP2729498A1 (de) 2011-07-06 2014-05-14 MorphoSys AG Therapeutische kombinationen von anti-cd20- und anti-gm-csf-antikörpern und verwendungen davon
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (de) 2012-10-31 2019-05-22 Takeda GmbH Lyophilisierte formulierung mit einer gm-csf-neutralisierenden verbindung
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
CA2944775A1 (en) * 2014-04-04 2015-10-08 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
US9714953B2 (en) 2014-04-04 2017-07-25 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
EP3691663A4 (de) 2017-10-02 2021-08-18 Humanigen, Inc. Verfahren zur behandlung von mit immuntherapie einhergehender toxizität unter verwendung eines gm-csf-antagonisten
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
WO2020118605A1 (zh) * 2018-12-13 2020-06-18 丁邦 抗体-肿瘤坏死因子α融合蛋白及其制法和应用
US20210284744A1 (en) * 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
EP0366707A1 (de) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoklonale antikörper gegen nierenzellen-karzinom
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
FR2723462B1 (fr) 1994-08-02 1996-09-06 Thomson Lcd Procede d'adressage optimise d'ecran a cristaux liquides et dispositif pour sa mise en oeuvre
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
EP2341075A1 (de) * 2000-03-01 2011-07-06 MedImmune, LLC Anti-rsv-f-protein-antikörper
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US7381801B2 (en) * 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies

Also Published As

Publication number Publication date
EP1530580B1 (de) 2011-05-11
US7714113B2 (en) 2010-05-11
EP1530580A2 (de) 2005-05-18
US7381801B2 (en) 2008-06-03
US20120029172A1 (en) 2012-02-02
US20100167395A1 (en) 2010-07-01
WO2003068920A2 (en) 2003-08-21
EP1530580A4 (de) 2006-02-01
WO2003068924A2 (en) 2003-08-21
ATE444308T1 (de) 2009-10-15
ES2365606T3 (es) 2011-10-07
AU2003215188A1 (en) 2003-09-04
AU2003215188A8 (en) 2003-09-04
EP1507859A4 (de) 2007-05-30
WO2003068920A9 (en) 2004-06-03
WO2003068920A8 (en) 2004-07-29
EP1507859A2 (de) 2005-02-23
US20090259027A1 (en) 2009-10-15
AU2003217386B2 (en) 2008-06-26
US7897743B2 (en) 2011-03-01
WO2003068924A3 (en) 2004-12-29
JP2006500905A (ja) 2006-01-12
EP1507859B1 (de) 2009-09-30
US20040053365A1 (en) 2004-03-18
US20060045876A1 (en) 2006-03-02
DE60329489D1 (de) 2009-11-12
WO2003068920A3 (en) 2004-07-01
AU2003217386A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
ATE509032T1 (de) Chimerizierte gm-csf antikörper
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
WO2005012493A3 (en) Anti-cd19 antibodies
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
ATE385806T1 (de) Fusionsproteine
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
MY142290A (en) Anti-il-6 antibodies compositions, methods and uses
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
MY154009A (en) Anti-alpha v beta 6 antibodies
TW200510459A (en) RG1 antibodies and uses thereof
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
WO2004093808A3 (en) Novel tumor-associated antigens
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody
CY1110844T1 (el) Πολυπεπτιδικα σκευασματα που προσδενουν to cd20
WO2005079267A3 (en) Methods for protein production

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties